A metabolic synthetic lethality of PI3K-driven cancer
Vahid Asnafi(Hôpital Necker-Enfants Malades), Olivier Hermine(Délégation Paris 5)
Cited by 0
Related Papers
Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
|PLoS ONE|2009|409
Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia
|The Journal of Experimental Medicine|2010|194
Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup
|Science Translational Medicine|2021|41